Produção Nacional
Revisado por pares
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria
2019; Massachusetts Medical Society; Volume: 380; Issue: 3 Linguagem: Inglês
10.1056/nejmoa1710775
ISSN1533-4406
AutoresMarcus Lacerda, Alejandro Llanos‐Cuentas, Srivicha Krudsood, Chanthap Lon, David Saunders, Rezika Mohammed, Daniel Yilma, Dhélio B. Pereira, Fe Esperanza Espino, Reginaldo Z. Mia, Raúl Chuquiyauri, Fernando Val, Martín Casapía, Wuelton Marcelo Monteiro, Marcelo Augusto Mota Brito, Mônica Regina Farias Costa, Nillawan Buathong, Harald Noedl, Ermias Diro, Sisay Getie, Kalehiwot M. Wubie, Alemseged Abdissa, Ahmed Zeynudin, Cherinet Abebe, Mauro Shugiro Tada, Françoise Brand, Hans‐Peter Beck, Brian Angus, Stephan Duparc, Jőrg‐Peter Kleim, Lynda Kellam, Victoria M. Rousell, Siôn W. Jones, Elizabeth Hardaker, Khadeeja Mohamed, Donna D. Clover, Kim Fletcher, John Breton, Cletus O. Ugwuegbulam, Justin A. Green, Gavin Koh,
Tópico(s)Neonatal Health and Biochemistry
ResumoTreatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed "radical cure"). Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P. vivax.
Referência(s)